Spectranetics today released data from a late breaking clinical trial of its Bridge occlusion balloon designed to reduce blood loss due to superior vena cava tears during lead extraction procedures, touting a 100% survival rate amongst patients treated with the balloon.
The company presented 1-year clinical experience data from the study today at the Heart Rhythm Society’s 38th Annual Scientific Sessions.
The Colorado Springs, Colo.-based company’s Bridge balloon is designed to reduce blood loss in the event of a tear and to provide a “bridge” to surgical intervention.
